Neogen Chemicals Ltd. (IN:NEOGEN)
:NEOGEN
Want to see IN:NEOGEN full AI Analyst Report?
Top Page
Neogen Chemicals Ltd.
(NEOGEN)
Select Model
Select Model
Rating:52Neutral
Price Target:
₹1,953.00
▲(68.81% Upside)
Action:Reiterated
Date:05/21/26
The score is held back primarily by weakened financial quality—margin compression, sharply higher leverage, and negative operating/free cash flow—raising execution and funding risk. Technicals are supportive with the stock trading above major moving averages, but valuation remains a headwind due to the very high P/E, only modestly offset by the dividend yield.
Positive Factors
Specialized bromine- and lithium-based chemistry
A focused specialty-chemicals model centered on bromine and lithium builds durable differentiation: these chemistries require technical know-how, tailored production and regulatory/quality controls, creating higher technical barriers to entry and longer product qualification cycles that support recurring revenue.
Negative Factors
Sharp margin compression
A marked decline in gross and net margins signals structural pressure from pricing, mix or rising input costs that can persist absent decisive product- or cost-led remediation. Sustained margin erosion reduces internal cash generation and weakens returns on invested capital over months to years.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized bromine- and lithium-based chemistry
A focused specialty-chemicals model centered on bromine and lithium builds durable differentiation: these chemistries require technical know-how, tailored production and regulatory/quality controls, creating higher technical barriers to entry and longer product qualification cycles that support recurring revenue.
Read all positive factors
Neogen Chemicals Ltd. (NEOGEN) vs. iShares MSCI India ETF (INDA)
Market Cap
₹50.92B
Dividend Yield0.09%
Average Volume (3M)9.36K
Price to Earnings (P/E)177.2
Beta (1Y)1.48
Revenue Growth10.86%
EPS Growth-17.60%
CountryIN
Employees588
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)9.88
Shares Outstanding26,381,674
10 Day Avg. Volume1,157
30 Day Avg. Volume9,357
Financial Highlights & Ratios
PEG Ratio-5.85
Price to Book (P/B)3.59
Price to Sales (P/S)3.40
P/FCF Ratio-3.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)17.97
Revenue Forecast (FY)₹12.52B
Neogen Chemicals Ltd. Business Overview & Revenue Model
Company Description
Neogen Chemicals Limited, founded in Thane, India, in 1989, is engaged in the manufacturing and supply of an extensive array of specialized chemical products. The company's comprehensive portfolio encompasses numerous organo-bromine compounds, inc...
How the Company Makes Money
Neogen makes money primarily by manufacturing and selling specialty chemical products and intermediates, with revenue recognized from customer orders/contracts for these materials. Key revenue streams typically include: (1) Bromine-based specialty...
Neogen Chemicals Ltd. Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
38
Negative
Cash Flow
24
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.00B | 8.62B | 7.78B | 6.91B | 6.86B | 4.87B |
| Gross Profit | 3.69B | 2.78B | 3.54B | 1.42B | 2.98B | 1.40B |
| EBITDA | 1.37B | 1.37B | 1.36B | 1.13B | 1.16B | 865.60M |
| Net Income | 260.50M | 287.50M | 348.30M | 356.50M | 499.70M | 446.30M |
Balance Sheet | ||||||
| Total Assets | 23.02B | 29.02B | 17.47B | 14.61B | 10.54B | 7.99B |
| Cash, Cash Equivalents and Short-Term Investments | 5.00B | 49.50M | 49.60M | 124.90M | 967.60M | 1.14B |
| Total Debt | 11.32B | 13.95B | 5.97B | 4.09B | 3.70B | 2.29B |
| Total Liabilities | 15.02B | 20.86B | 9.58B | 7.01B | 5.71B | 3.60B |
| Stockholders Equity | 8.00B | 8.16B | 7.89B | 7.60B | 4.83B | 4.39B |
Cash Flow | ||||||
| Free Cash Flow | -4.17B | -8.93B | -1.22B | -3.32B | -1.34B | -1.69B |
| Operating Cash Flow | -2.46B | -3.37B | 1.96B | -291.50M | -303.50M | 14.10M |
| Investing Cash Flow | -1.13B | -4.14B | -3.17B | -2.16B | -944.60M | -1.46B |
| Financing Cash Flow | 4.66B | 7.51B | 1.13B | 2.37B | 1.00B | 1.88B |
Neogen Chemicals Ltd. Technical Analysis
Positive
1156.90
Price Trends
1709.08
Positive
1505.93
Positive
1419.46
Positive
Market Momentum
89.14
Positive
57.11
Neutral
55.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NEOGEN, the sentiment is Positive. The current price of 1156.9 is below the 20-day moving average (MA) of 1891.53, below the 50-day MA of 1709.08, and below the 200-day MA of 1419.46, indicating a bullish trend. The MACD of 89.14 indicates Positive momentum. The RSI at 57.11 is Neutral, neither overbought nor oversold. The STOCH value of 55.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NEOGEN.
Neogen Chemicals Ltd. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ₹91.72B | 50.90 | ― | 0.62% | -2.29% | -3.26% | |
63 Neutral | ₹71.53B | 41.60 | ― | 0.97% | 2.00% | 6.14% | |
63 Neutral | ₹40.34B | 28.21 | ― | 0.05% | 11.28% | 10.48% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
52 Neutral | ₹50.92B | 177.20 | ― | 0.09% | 10.86% | -17.60% | |
49 Neutral | ₹28.00B | 66.57 | ― | 0.07% | 32.18% | 636.02% | |
48 Neutral | ₹42.51B | 54.03 | ― | 0.29% | -4.65% | -30.36% |
* Basic Materials Sector Average
IN:NEOGEN
Neogen Chemicals Ltd.
1,930.75
336.92
21.14%
IN:ALKYLAMINE
Alkyl Amines Chemicals Limited
1,843.75
-215.26
-10.45%
IN:BALAMINES
Balaji Amines Limited
2,137.35
757.63
54.91%
IN:LXCHEM
Laxmi Organic Industries Ltd.
152.00
-40.27
-20.94%
IN:TATVA
Tatva Chintan Pharma Chem Limited
1,195.00
279.31
30.50%
IN:VISHNU
Vishnu Chemicals Limited
600.70
57.89
10.66%
Neogen Chemicals Ltd. Corporate Events
Neogen Chemicals holds virtual EGM to clear equity issue and address investor queries
Mar 29, 2026
Neogen Chemicals Ltd. held an Extraordinary General Meeting on March 29, 2026, via video conferencing and other audio-visual means, in compliance with Ministry of Corporate Affairs and SEBI guidelines for electronic shareholder participation. The ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.